Article Details

Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne ...

Retrieved on: 2022-10-12 09:17:09

Tags for this article:

Click the tags to see associated articles and topics

Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne .... View article details on hiswai:

Excerpt

AOC 1044 is the first antibody oligonucleotide conjugate (AOC™) of ... AOC 1044 consists of a proprietary monoclonal antibody that binds to the ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up